Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Curcumin Also Inhibits Metastasis from Prostate Cancer

By BiotechDaily International staff writers
Posted on 23 Oct 2012
Researchers have now shown that curcumin, the key medicinal ingredient of turmeric, can also inhibit formation of metastases from prostate cancer, and have identified the main mechanism by which it does so.


Powdered turmeric has long been used in traditional medicine to treat osteoarthritis and other illnesses. Studies have shown that its active ingredient, the polyphenol curcumin, inhibits inflammatory reactions. A research team led by PD Dr. Beatrice Bachmeier of the Ludwig-Maximilians-University Munich (Munich, Germany) has been studying the effectiveness and the mode of action of curmumin in inhibition of cancer metastasis. In a previous study, Dr. Bachmeier and colleagues had demonstrated that the substance reduces statistically significantly the formation of lung metastases in an animal model of advanced breast cancer.


Prostate cancer is often diagnosed only after metastatic tumors have formed in other organs and emerging evidence suggests that chronic inflammation is a major risk factor for the development and metastatic progression of prostate cancer. The new study, published early online October 5, 2012, in the journal Carcinogenesis, was designed to investigate the efficacy of curcumin in preventing prostate cancer metastases and to determine its mechanism of action. The researchers first examined the molecular processes that are abnormally regulated in the carcinoma cells. Prostate and breast cancers are often associated with latent or chronic inflammatory reactions and, in both cases, the tumor cells were found to abnormally produce proinflammatory immunomodulators including the cytokines CXCL1 und CXCL2. They then observed that, among other inhibiting effects, curcumin specifically decreased the expression of these two proteins and other important metastasis-promoting factors. Furthermore, in a mouse model this effect was correlated with a decline in the incidence of metastases.


Since curcumin is well tolerated, it could be suitable for use in reducing metastatic potential by chemoprevention - for prophylactic use (primary prevention) and/or for the suppression of metastases where an established tumor is already present (secondary prevention). “This does not mean that the compound should be seen as a replacement for conventional therapies. However, it could play a positive role in [prevention or treatment]. In this context the fact that the substance is well tolerated is very important,” said Dr. Bachmeier.


A daily intake of up to 8 g of curcumin is regarded as safe, and its anti-inflammatory properties have long been exploited in traditional medicine. For prophylaxis, men with benign hyperplasia of the prostate (BHP) are one possible target group, as are women with a family history of breast cancer. The agent might also be valuable as a supplement to certain cancer therapies. Since curcumin’s beneficial effects must first be examined in controlled clinical tests, Dr. Bachmeier and colleagues are presently planning a clinical trial in patients suffering from therapy-resistant prostate carcinoma.

Related Links:

Ludwig-Maximilians-University Munich




WATERS CORPORATION

Channels

Genomics/Proteomics

view channel
Image: Outer membrane vesicles released by Bacteroides thetaiotaomicron may help initiate inflammatory bowel disease (Photo courtesy of Wandy Beatty, Washington University School of Medicine).

Interaction of Gut Cells with Bacterial Outer Membrane Vesicles Triggers Inflammatory Bowel Disease in Mouse Model

Interaction of bacterial outer membrane vesicles (OMVs) harboring sulfatase activity with the cells lining the gut has been implicated as a key step in the development of inflammatory bowel diseases (IBDs)... Read more

Drug Discovery

view channel
Image: Molecular model of the anti-cancer drug 5-fluorouracil (Photo courtesy of Wikimedia Commons).

Novel Microcapsule Approach Reduces Toxic Side Effects of Chemotherapy

Cancer researchers have reduced chemotherapy's toxic side effects by using nanoporous capsules to transport an enzyme to the site of a tumor where it is activated by a selective heating process to convert... Read more

Lab Technologies

view channel
Image: The gene assembly robot, the GeneTheatre (Photo courtesy of Analytik Jena AG).

Genomic Research Laboratories Await New Compact Liquid Handling System

A small footprint benchtop liquid handler that automates multiple gene assembly tasks and associated procedures such as PCR setup is now available for use by biotech and genomic research laboratories.... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

02 Jun 2015 - 03 Jun 2015
15 Jun 2015 - 18 Jun 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.